The article "Novel gene therapies for precision pain management" has been published by Pharmafile
Navega has been featured in the special issue of Pharmafile dedicated to Pain Management
San Diego, California. December 31, 2019.
Fernando Aleman, Navega's CSO, has been invited to participate in the latest issue of Pharmafile (London, UK) which focused on Pain Management in this edition. Pharmafile is a bi-annual guide which focuses on 3 therapeutic areas per edition and collates commissioned thought leadership, opinion, and market analysis pieces from a range of players in the industry. In this thought-led article, Dr. Aleman emphasizes the need of alternative approaches to manage pain and specifically focuses on the genetics of pain and gene therapy solutions. The article called "Novel gene therapies for precision pain management" can be found here.
About Navega Therapeutics Inc. | Navega is a preclinical stage company pursuing a radically different approach to treat chronic pain and tackle the opioid epidemic. Our gene therapy platform has the advantage of being highly specific and long-lasting, which has not been achieved by small molecules thus far. Our approach includes addressing different types of pain in order to improve the quality of life of millions of patients.